Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Stephen O who wrote (8634)	11/18/2004 11:13:04 PM
From: Robohogs	Read Replies (2) \| Respond to of 9523

I notice Celebrex AND Lipitor missing from the list. Jon

To: Stephen O who wrote (8634)	11/19/2004 12:03:50 AM
From: Spekulatius	Read Replies (1) \| Respond to of 9523

re COX-2. I don't have a biological/medical background but i think the clinical data so far supports the assumption that the Vioxx mortality increase is not due to a class effect. I would also argue that there is a difference between mice and men :-). Last not least, drugs like Aspirin are Cox-2 suppressors as well, just not selective (they suppress Cox-1 as well), yet they still are know to protect the heart. So I think it is quite unlikely from this viewpoint that the mortality increase with Vioxx is due to a Class effect.